Adrian Hargrave, CEO of SEEEN, explains how the new funds will accelerate customer growth Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOncimmune Regulatory News (ONC)

Share Price Information for Oncimmune (ONC)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 14.00
Bid: 14.00
Ask: 15.40
Change: -2.95 (-16.71%)
Spread: 1.40 (10.00%)
Open: 16.00
High: 16.40
Low: 14.00
Prev. Close: 17.65
ONC Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

PUBLIC DISCLOSURE OF TRANSACTIONS BY PDMR

30 Nov 2016 17:47

RNS Number : 6216Q
Oncimmune Holdings PLC
30 November 2016
 

30 November 2016

 

Oncimmune Holdings plc

("Oncimmune" or the "Company")

 

NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PDMR

 

Oncimmune Holdings plc (AIM: ONC.L), a leading early cancer detection company developing and commercialising its proprietary EarlyCDT® platform technology, today announces that on 30 November 2016, options over ordinary shares of 1 pence each in the capital of the Company ("Ordinary Shares") were awarded to Dan Calvo, President of Oncimmune (USA) LLC, a PDMR, as well as to certain other US staff, under the Company's Oncimmune Holdings Plc Incentive Stock Option Plan (as amended from the Oncimmune Limited Incentive Stock Option Plan that became effective 27 July 2009) as follows:

 

Name

Position

Number of share options awarded

Option exercise price per share (pence)

Interest in issued share capital (%)

Dan Calvo

President of Oncimmune (USA) LLC

10,151

118.5

0.02

 

The options are subject to the rules of the Incentive Stock Option Plan and vest in five equal annual parts, the first fifth vesting on 29 November 2017 and each year thereafter for a further four years, subject to continued employment. The options are exercisable at 118.5 pence, being the mid-market closing price of the Ordinary Shares on 29 November 2016

 

For further information:

 

Oncimmune Holdings plc

Geoffrey Hamilton-Fairley, Chief Executive Officer

contact@oncimmune.co.uk

 

Zeus Capital Limited (Nominated Adviser and Broker)

Phil Walker, Giles Balleny, Dominic Wilson

+44 (0) 203 829 5000

 

Media enquiries:

Consilium Strategic Communications

Chris Gardner, Mary-Jane Elliott, Matthew Neal, Lindsey Neville

oncimmune@consilium-comms.com

+44 (0) 20 3709 5708

 

 

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name 

Dan Calvo

2

Reason for the notification

a)

Position/status 

President of Oncimmune (USA) LLC

b)

Initial notification/Amendment

 

Initial Notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Oncimmune Holdings plc

b)

LEI

N/A

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

 Identification code

options over Ordinary Shares - Oncimmune Holdings Plc Incentive Stock Option Plan

 

ISIN GB00BYQ94H38

b)

Nature of the transaction

 

Grant of options over Ordinary Shares

c)

Price(s) and volume(s)

 

Price(s)

Volume(s)

N/A

10,151

d)

Aggregated information

 

Price(s)

Volume(s)

N/A

10,151

e)

Date of the transaction

 

30 November 2016

f)

Place of the transaction 

N/A

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
DSHURSBRNNAAOAA
Date   Source Headline
2nd Nov 20217:00 amRNSFull year results and progress update
2nd Nov 20217:00 amRNSChange of Adviser
27th Oct 20214:35 pmRNSPrice Monitoring Extension
25th Oct 20214:40 pmRNSSecond Price Monitoring Extn
25th Oct 20214:35 pmRNSPrice Monitoring Extension
25th Oct 20217:00 amRNSNotice of Full Year results
20th Sep 20217:00 amRNSAgreement with pharma company to profile patients
15th Sep 202111:08 amRNSBlock Listing Six Monthly Return
23rd Aug 20217:00 amRNSThree-year follow-up data for the ECLS trial
23rd Jul 20217:00 amRNSAgreement signed with major cancer center
22nd Jul 20217:00 amRNSValidation of ImmunoINSIGHTS service in COVID-19
1st Jul 20217:00 amRNSTotal Voting Rights
8th Jun 20217:00 amRNSFull Year Trading Update
28th May 20217:30 amRNSNotice of FY21 Trading Update
5th May 20217:03 amRNSReturn of China Rights to EarlyCDT
4th May 202112:23 pmRNSTotal Voting Rights
8th Apr 20217:00 amRNSHolding(s) in Company
7th Apr 20212:05 pmRNSSecond Price Monitoring Extn
7th Apr 20212:00 pmRNSPrice Monitoring Extension
6th Apr 20211:48 pmRNSBlock Listing Six Monthly Return
6th Apr 20217:00 amRNSAgreements signed with Roche and Cedars-Sinai
6th Apr 20217:00 amRNSHolding(s) in Company
1st Apr 20217:00 amRNSHolding(s) in Company
25th Mar 20212:01 pmRNSResult of Oversubscribed Equity Placing
25th Mar 20217:45 amRNSLaunch of Equity Placing via Accelerated Bookbuild
15th Mar 20217:00 amRNSIssue of Equity and Total Voting Rights
1st Mar 20217:00 amRNSTotal Voting Rights
15th Feb 20217:00 amRNSInterim Results
25th Jan 20217:00 amRNSNotice of Half Year Results
19th Jan 20214:17 pmRNSDirectorate Change
18th Jan 202111:37 amRNSHolding(s) in Company
14th Jan 20219:49 amRNSPDMR Dealing
6th Jan 202110:27 amRNSTotal Voting Rights
18th Dec 20207:00 amRNSPDMR Dealing
15th Dec 20207:00 amRNSAutoantibody profiles publication for RA treatment
14th Dec 20207:00 amRNSEarlyCDT Lung blood test launch into the NHS
30th Nov 202011:21 amRNSResults of Annual General Meeting
11th Nov 20207:00 amRNSAgreement with Augmenta Bioworks
9th Nov 20207:00 amRNSNotice of AGM and Posting of Annual Report
30th Oct 20207:00 amRNSFull year results and progress update
28th Oct 20207:00 amRNSClinical study initiated by Biodesix in US
21st Oct 20207:00 amRNSAbstracts of Studies using EarlyCDT Lung
19th Oct 20208:21 amRNSReplacement: Notice of Full Year Results
19th Oct 20207:00 amRNSNotice of Full Year Results ended 31 May 2020
13th Oct 20207:00 amRNSAgreement with Cedars-Sinai to Profile COVID-19
8th Oct 202011:05 amRNSSecond Price Monitoring Extn
8th Oct 202011:00 amRNSPrice Monitoring Extension
6th Oct 20207:00 amRNSUK Government funding for tool for use in COVID-19
23rd Sep 20207:00 amRNSProfiling samples from Genentech
15th Sep 20202:00 pmRNSBlock Admission

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.